8-KOther EventsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Corporate Update (Mar 3, 2020)

Filed March 3, 2020For Securities:TMO

Summary

Thermo Fisher Scientific Inc. announced on March 3, 2020, that it has entered into a Business Combination Agreement to acquire QIAGEN N.V. The acquisition will be executed through a wholly-owned subsidiary of Thermo Fisher commencing a public tender offer to purchase all issued ordinary shares of QIAGEN. This strategic move represents a significant growth initiative for Thermo Fisher, aiming to expand its offerings and market presence. Investors should note that this is a proposed transaction, and its completion is subject to various conditions, including regulatory approvals and the successful outcome of the tender offer. The company has provided supplemental information regarding this transaction via an investor presentation, and further details will be disclosed in subsequent filings and official offer documents.

Key Highlights

  • 1Thermo Fisher Scientific is launching a tender offer to acquire QIAGEN N.V.
  • 2The transaction is structured as a business combination through a wholly-owned acquisition subsidiary.
  • 3A joint press release announcing the Business Combination Agreement was issued on March 3, 2020.
  • 4Thermo Fisher has also provided supplemental investor information via a presentation.
  • 5The completion of the acquisition is contingent upon customary closing conditions, including regulatory approvals.
  • 6Investors are advised to review official tender offer materials for detailed terms and conditions.
  • 7The filing includes a broad list of risks and uncertainties associated with the transaction.

Frequently Asked Questions

The main event is the announcement of Thermo Fisher Scientific's agreement to acquire QIAGEN N.V. through a public tender offer initiated by a subsidiary of Thermo Fisher.

The filing does not disclose the specific transaction price for QIAGEN. It announces the execution of a Business Combination Agreement and the commencement of a tender offer, but the financial terms are expected to be detailed in subsequent offer documents.

The completion of the acquisition is subject to the terms and conditions of the Business Combination Agreement, which include obtaining necessary regulatory approvals and the successful outcome of the tender offer by Thermo Fisher's subsidiary to acquire QIAGEN shares.

Investors can find more detailed information in the official tender offer materials, including the offer document, letter of transmittal, and related filings (Schedule TO for Thermo Fisher, Schedule 14D-9 for QIAGEN) to be filed with the SEC. These documents will be made available on the SEC's website, as well as QIAGEN's and Thermo Fisher's investor relations websites.